Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
ELCC 2018
The 8th European Lung Cancer Conference
Access to all presentations that took place at ELCC 2018 in Geneva, Switzerland
Presentation Date(s):- Apr 11 - 14, 2018
- Total Presentations: 407
-
+
Welcome reception
- Type: Welcome reception
- Presentations: 0
- Coordinates: 4/11/2018, 13:00 - 13:30, Hall 1
-
+
Opening and welcome
- Type: Opening and welcome
- Presentations: 4
- Moderators:L. Paz-Ares
- Coordinates: 4/11/2018, 13:30 - 13:45, Room B
-
+
Welcome to the Congress
13:30 - 13:35 | Presenter: M. Perol
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Introduction to ESMO
13:35 - 13:40 | Presenter: S. Peters
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Introduction to IASLC
13:40 - 13:45 | Presenter: G. Scagliotti
- Abstract
No abstract available for this presentation
-
+
2018 HHH Award Winner Introduction
13:45 - 13:45 | Presenter: S. Peters
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
HHH Award Keynote Lecture
- Type: Keynote Lecture
- Presentations: 1
- Moderators:S. Peters
- Coordinates: 4/11/2018, 13:45 - 14:15, Room B
-
+
The power of the multiple H
13:45 - 14:15 | Presenter: F. Barlesi
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
Combined treatment stage III
- Type: Educational session
- Presentations: 5
- Moderators:S. Peters
- Coordinates: 4/11/2018, 14:30 - 16:00, Room A
-
+
When concurrent chemo-radiotherapy is not the preferred choice
14:30 - 14:50 | Presenter: P. Fournel
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Are current NTCP models useful for predicting radiation-induced toxicity?
14:50 - 15:10 | Presenter: D. De Ruysscher
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Surgical salvage of recurrences following CT-RT: Indications and outcomes
15:10 - 15:30 | Presenter: C. Dickhoff
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Immunotherapy in the stage III paradigm: Rationale and clinical data
15:30 - 15:50 | Presenter: S. Peters
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Q&A
15:50 - 16:00
- Abstract
No abstract available for this presentation
-
+
First line for oncogene addicted lung cancer
- Type: Educational session
- Presentations: 5
- Moderators:J. Wolf
- Coordinates: 4/11/2018, 14:30 - 16:00, Room B
-
+
Is PFS still a relevant endpoint for first-line TKIs?
14:30 - 14:50 | Presenter: S. Ramalingam
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
First vs second vs third generation EGFR TKI
14:50 - 15:10 | Presenter: J. Wolf
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Key factors that determine the selection of first-line ALK inhibtiors
15:10 - 15:30 | Presenter: F. Blackhall
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
The role of first-line combination therapy for oncogene addicted lung cancer
15:30 - 15:50 | Presenter: T. Seto
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Q&A
15:50 - 16:00
- Abstract
No abstract available for this presentation
-
+
Coffee break
- Type: Coffee break
- Presentations: 0
- Coordinates: 4/11/2018, 16:00 - 16:30, Hall 1
-
+
Early stage NSCLC: Where do we stand in 2018?
- Type: Educational session
- Presentations: 5
- Moderators:S. Siva
- Coordinates: 4/11/2018, 16:30 - 18:00, Room A
-
+
Guidelines for surgery in ground glass opacities
16:30 - 16:50 | Presenter: K. Suzuki
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Pathology and biomarkers in resected NSCLC
16:50 - 17:10 | Presenter: E. Brambilla
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Neoadjuvant immunotherapy in early-stage NSCLC
17:10 - 17:30 | Presenter: P. Forde
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Stereotactic radiotherapy for early stage NSCLC
17:30 - 17:50 | Presenter: S. Siva
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Q&A
17:50 - 18:00
- Abstract
No abstract available for this presentation
-
+
First line for non-oncogene addicted lung cancer
- Type: Educational session
- Presentations: 5
- Moderators:M. Reck
- Coordinates: 4/11/2018, 16:30 - 18:00, Room B
-
+
First-line chemotherapy in NSCLC: Where do we stand?
16:30 - 16:50 | Presenter: R.A. Stahel
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Immunotherapy in the first-line setting: What have we achieved?
16:50 - 17:10 | Presenter: M. Reck
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
First-line therapy in PS2 and elderly patients: Any new signals?
17:10 - 17:30 | Presenter: E. Quoix
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
First-line therapy: What might we expect for the future?
17:30 - 17:50 | Presenter: G. Scagliotti
- Abstract
No abstract available for this presentation
-
+
Q&A
17:50 - 18:00
- Abstract
No abstract available for this presentation
-
+
Industry Satellite Symposium 2
- Type: Industry Satellite Symposium
- Presentations: 1
- Coordinates: 4/11/2018, 18:30 - 20:00, Room A
-
+
Presentation
18:30 - 20:00
- Abstract
No abstract available for this presentation
-
+
Immunotherapy and next-generation TKIs: From second to frontline treatment
- Type: Poster Discussion session
- Presentations: 18
- Moderators:P. Garrido Lopez
- Coordinates: 4/12/2018, 07:45 - 09:00, Room A
-
+
134PD - Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150)
10:54 - 10:54 | Presenter: M. Reck
- Abstract
Loading... -
+
136PD_PR - 3-year survival and duration of response in randomized phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC (POPLAR)
10:54 - 10:54 | Presenter: J. Mazieres
- Abstract
Loading... -
+
137PD - Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC)
10:54 - 10:54 | Presenter: O. Juan
- Abstract
Loading... -
+
Invited Discussant 134PD, 136PD and 137PD
07:45 - 07:57 | Presenter: P. Garrido Lopez
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Discussion
07:57 - 08:07
- Abstract
No abstract available for this presentation
-
+
138PD_PR - Patient-reported outcomes (PROs) in ALEX: A phase III study of alectinib (ALEC) vs crizotinib (CRIZ) in non-small-cell lung cancer (NSCLC)
10:54 - 10:54 | Presenter: M. Perol
- Abstract
Loading... -
+
139PD - Patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC)
10:54 - 10:54 | Presenter: N. Leighl
- Abstract
Loading... -
+
Invited Discussant 138PD and 139PD
08:07 - 08:17 | Presenter: S. Ekman
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Discussion
08:17 - 08:22
- Abstract
No abstract available for this presentation
-
+
140PD - Complex epidermal growth factor receptor (EGFR) mutations and responses to tyrosine kinase inhibitors (TKIs) in advanced lung adenocarcinomas
10:54 - 10:54 | Presenter: B. Zhang
- Abstract
Loading... -
+
141PD - A prospective study of molecular testing status in the EGFR mutation positive NSCLC patients with disease progression during EGFR TKI treatment (REMEDY study)
10:54 - 10:54 | Presenter: K. Kanai
- Abstract
Loading... -
+
142PD - Detection of EGFR mutations in cerebrospinal fluid of EGFR-mutant lung adenocarcinoma with brain metastases
10:54 - 10:54 | Presenter: L. Shi
- Abstract
Loading... -
+
Invited Discussant 140PD, 141PD and 142PD
08:22 - 08:34 | Presenter: S. Ortiz-Cuaran
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Discussion
08:34 - 08:44
- Abstract
No abstract available for this presentation
-
+
143PD - Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7
10:54 - 10:54 | Presenter: J.C. Yang
- Abstract
Loading... -
+
144PD - Leptomeningeal metastases in EGFR-mutated non-small cell lung carcinoma: Management after tyrosine kinase inhibitors
10:54 - 10:54 | Presenter: R. Flippot
- Abstract
Loading... -
+
Invited Discussant 143PD and 144PD
08:44 - 08:54 | Presenter: E. Wauters
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
Discussion
08:54 - 08:59
- Abstract
No abstract available for this presentation